PPT-NCI Division of Cancer Prevention

NCI Division of Cancer Prevention Ongoing Activities at Frederick Facilities Presented By Lori Minasian MD Robert Shoemaker PhD October 1 2015 Overview of Mission and Purpose Overview of Mission and Purpose. Essential . and Virtuous Aspiration or . Mentoring . Virgins for the Whorehouse?. April 14th, 2014. David I. Quinn MBBS (Hons) PhD FRACP FACP. Associate Professor of Medicine. Chief, Section . f . GU Medical Oncology. (NCI-MATCH or EAY131). Interim Analysis Results. Study Chairs: Keith . T. Flaherty. 1. , . Alice P. Chen. 2. , . Peter J. O'Dwyer. 3. , . Barbara . A. Conley. 2. , Stanley R. Hamilton. 4. , . Mickey . Assistant Professor. Virginia Commonwealth University. What is cancer of unknown primary?. Clinical syndrome representing many different types of cancer. Heterogeneous . group: many . primary sites with varying . (NCI-MATCH / EAY131). A phase II precision medicine cancer trial . Co-developed by the ECOG-ACRIN Cancer Research Group and the National Cancer Institute. Version Date: . 06/20/2018. On Behalf of the NCI-MATCH Study Leadership. S. Percy Ivy, MD. Associate Chief, Senior Investigator. Investigational Drug Branch, National Cancer Institute. ivyp@ctep.nci.nih.gov. . National Cancer Institute. . National Cancer Institute. (ETCTN). Central IRB Education Day. 28 April 2015. Percy Ivy, MD. Associate Chief, Investigational Drug Branch. Cancer Therapy Evaluation . Program. Program Director, Experimental Therapeutics Clinical Trials Network. Using Research to Inform Policy and Practice Samantha Crane Valerie Bradley Julie Bershadsky Stephanie Giordano NCI-DD and NCI-AD National Overview How did NCI Begin? NCI began in 1997to measure track state performance in DD systems NCI in 2017 What’s new in 2017? Presented by The NCI Team NCI Annual Meeting | August 1-2, 2017 Agenda New team members Highlights from 2015-2016 NCI reports ODESA update 2016-2017 Events and presentations 2 NCI Grant Funding for Trainees PredoctoralPostdoctoralEarly Stage PI K01, K08 F30, F31, F99*/K00 F32, K99*/R00, K22*Open to Applicants with U.S. VisasMany Entry Points Institutional Awards: !,'-./0/-*012!,3'$-0&!!!!!"#$%&'(%!)*+),- !)&+$- !.+!)&+$-&##.+(!)*+),- !$&!0-&2&$.+(!10,).*#.=,35!2'#$.3.1).0#.+*-!*+3!)&20-,%,+1.4,!)*+),-!-,1,*-)%5 !*00-&0-.*$,!$-,*$2,+$!;*1,3!&+!1).,+$.9.)!A+& Sylvia . O’Neill, . MD . Executive Director . . Clinical Research Organization . Teresa . Cardoso, . MS,BSN,RN. . Clinical . Trial Nurse . Educator. Clinical . DO cancer slim Raja Mazumder, Lynn Schriml, Elvira Mitraka. NCBI . Donna . Maglott. EBI . . Sira. . Sarntivijai. NCI EVS . Sherri . de . Coronado. MGI . The NCI-H358 cells were treated with avutometinib for 72 h. Cell viability was determined using the CCK-8 assay. Data are representative of three independent experiments.. Figure S2. Knockdown effect of . Lalitha K. Shankar, MD, PhD,. Cancer Imaging Program, NCI. March 26, 2018. NCI Planning Committee. Jeff Abrams, Barry Kramer, Paul Jacobsen (DCTD, DCP & DCCPS) . Lalitha Shankar, Bhupinder Mann, Carmen Allegra, Shakuntala Malik, Larissa Korde, Nita Seibel, Worta McCaskill-Stevens and Anne Menkens.